Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(14%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_3
1
14%
Ph phase_1
3
43%
Ph phase_2
2
29%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

recruiting114%
completed686%

Recent Activity

1 active trials
Showing 5 of 7
completedphase_3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

NCT06374394
recruitingphase_2

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

NCT07215520
completedphase_1

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

NCT05938075
completedphase_1

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373485
completedphase_2

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373472
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06374394Phase 3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Completed
NCT07215520Phase 2

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

Recruiting
NCT05938075Phase 1

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

Completed
NCT05373485Phase 1

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Completed
NCT05373472Phase 2

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Completed
NCT05116748

COVID19 Vaccine in SOT Adult Recipients

Completed
NCT05144139Phase 1

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7